Real shockwave therapy has been shown to activate endogenous stem cells. It is the first time in erectile dysfunction history that we might change a primary underlying pathology and make the situation more responsive to symptomatic treatment or to where the person doesn’t even need symptomatic treatment.

LI-ESWT is a revolutionary treatment of ED, and probably possesses unprecedented qualities that can rehabilitate erectile tissue. The clinical improvement in subjective erectile function together with the significant improvement in penile hemodynamics following LI-ESWT confirm that LI-ESWT has unique properties that may create a new standard of care for men with ED.

Li-ESWT significantly increased EdU + cells within penile erectile tissues ( P < .01) at 48 hours and 1 week.

LI-ESWT demonstrated a positive long term clinical effect with improvement in erectile function of Indian men with vasculogenic ED who were prior responders to PDE5i therapy. The efficacy and tolerability of this treatment, coupled with its long term benefits and rehabilitative characteristics, make it an attractive new therapeutic option for men with vasculogenic erectile dysfunction.

There appears to be substantial, statistical advantages with the unfocused SoftWave therapy when compared to radial SWT.

Significant increases in the duration of erection and penile rigidity, and significant improvement in penile endothelial function were demonstrated. Ten men did not require any PDE5-I therapy after 6-mo follow-up. No pain was reported from the treatment and no adverse events were noted during follow-up.

The preliminary results of LI-ESWT in the treatment of ED with the MTS urogold100® and applicator OP155 are promising and indicate a clinically significant improvement in both, the IIEF and EHS by this technology.

The present trial shows the tolerability and clinical efficacy of low-intensity extracorporeal shockwave therapy in a subgroup of patients with erectile dysfunction.

Once weekly low intensity shockwave improved erections sufficient for intercourse.

The beneficial effect of low intensity shockwave therapy for erectile dysfunction exceeds 2 years in the majority of patients.

Low intensity shockwave improved erections sufficient for intercourse without side effects

Post treatment average testosterone levels improved 45% in patietns with no side effects. Patients reported no discomfort during or after treatment.

It has been demonstrated that ESWT is an effective and safe treatment for CPPS. Due to high prevalence of CPPS and none specific treatment, ESWT should be considered an effective and safe treatment alternative.

• The Journal of Sexual Medicine

In this prospective study, 1 month of moderate LIST treatment led to partial recovery of erectile function at one-month follow up, as the amount of positive SEP3 responders significantly increased 4 times and the average IIEF-5 score improved 8 times in the active group compared to the sham control group which, showed no placebo-effect.

LESWT can partially ameliorate DM-associated ED by promoting regeneration of nNOS-positive nerves, endothelium, and smooth muscle in the penis.

the principles of low intensity ESWT (Li-ESWT) for erectile dysfunction (ED) were introduced to show for the first time that ESWT can successfully treat patients suffering from ED.

Low-intensity extracorporeal shock wave therapy (LI-ESWT) is a novel treatment for erectile dysfunction (ED).

Low intensity extracorporeal shock wave therapy significantly improved erectile function in GK rats to the same extent as sildenafil.

ESWT may be an effective and safe treatment for lessening of penile plaques and relieving pain for men with PD.

ESWT may resolve pain in PD patients. Data on EHS does imply that the treatment potentially may recover natural erection in PDE-5i responders. ESWT seems to be able to resolve pain in CPP patients in the short term.

In patients with PD, ESWT leads to pain resolution and ameliorates both EF and QoL.

ESWT significantly improves the cavernosal artery velocity, thereby supporting the theory of angiogenesis. ESWT improves all the domains of IIEF including Erectile Function, Sexual Desire, Sexual Satisfaction, Orgasm and Overall Satisfaction.

Our results support SWT as an effective and safe first-line treatment for Peyronie’s disease.

Based on our findings, ESWT could be considered a safe and efficient minimally invasive option for the management of the patients suffering from PD.

In a carefully selected group of men with PD, LiESWT appears to be safe, has moderate efficacy and is associated with high patient satisfaction rate in the short term.